Literature DB >> 12093882

Strategies for an HIV vaccine.

Norman L Letvin1.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 12093882      PMCID： PMC151036          DOI： 10.1172/JCI15985

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  27 in total

1.  Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.

Authors:  D H Barouch; S Santra; J E Schmitz; M J Kuroda; T M Fu; W Wagner; M Bilska; A Craiu; X X Zheng; G R Krivulka; K Beaudry; M A Lifton; C E Nickerson; W L Trigona; K Punt; D C Freed; L Guan; S Dubey; D Casimiro; A Simon; M E Davies; M Chastain; T B Strom; R S Gelman; D C Montefiori; M G Lewis; E A Emini; J W Shiver; N L Letvin
Journal:  Science       Date:  2000-10-20       Impact factor: 47.728

2.  Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

Authors:  R R Amara; F Villinger; J D Altman; S L Lydy; S P O'Neil; S I Staprans; D C Montefiori; Y Xu; J G Herndon; L S Wyatt; M A Candido; N L Kozyr; P L Earl; J M Smith; H L Ma; B D Grimm; M L Hulsey; J Miller; H M McClure; J M McNicholl; B Moss; H L Robinson
Journal:  Science       Date:  2001-04-06       Impact factor: 47.728

3.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.

Authors:  J R Mascola; G Stiegler; T C VanCott; H Katinger; C B Carpenter; C E Hanson; H Beary; D Hayes; S S Frankel; D L Birx; M G Lewis
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

4.  Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV.

Authors:  I Ourmanov; C R Brown; B Moss; M Carroll; L Wyatt; L Pletneva; S Goldstein; D Venzon; V M Hirsch
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

5.  A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers.

Authors:  T G Evans; M C Keefer; K J Weinhold; M Wolff; D Montefiori; G J Gorse; B S Graham; M J McElrath; M L Clements-Mann; M J Mulligan; P Fast; M C Walker; J L Excler; A M Duliege; J Tartaglia
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

6.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group.

Authors:  T C Quinn; M J Wawer; N Sewankambo; D Serwadda; C Li; F Wabwire-Mangen; M O Meehan; T Lutalo; R H Gray
Journal:  N Engl J Med       Date:  2000-03-30       Impact factor: 91.245

7.  Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection.

Authors:  M A Egan; W A Charini; M J Kuroda; J E Schmitz; P Racz; K Tenner-Racz; K Manson; M Wyand; M A Lifton; C E Nickerson; T Fu; J W Shiver; N L Letvin
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

8.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

Authors:  John W Shiver; Tong-Ming Fu; Ling Chen; Danilo R Casimiro; Mary-Ellen Davies; Robert K Evans; Zhi-Qiang Zhang; Adam J Simon; Wendy L Trigona; Sheri A Dubey; Lingyi Huang; Virginia A Harris; Romnie S Long; Xiaoping Liang; Larry Handt; William A Schleif; Lan Zhu; Daniel C Freed; Natasha V Persaud; Liming Guan; Kara S Punt; Aimin Tang; Minchun Chen; Keith A Wilson; Kelly B Collins; Gwendolyn J Heidecker; V Rose Fernandez; Helen C Perry; Joseph G Joyce; Karen M Grimm; James C Cook; Paul M Keller; Denise S Kresock; Henryk Mach; Robert D Troutman; Lynne A Isopi; Donna M Williams; Zheng Xu; Kathryn E Bohannon; David B Volkin; David C Montefiori; Ayako Miura; Georgia R Krivulka; Michelle A Lifton; Marcelo J Kuroda; Jörn E Schmitz; Norman L Letvin; Michael J Caulfield; Andrew J Bett; Rima Youil; David C Kaslow; Emilio A Emini
Journal:  Nature       Date:  2002-01-17       Impact factor: 49.962

9.  Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes.

Authors:  Dan H Barouch; Jennifer Kunstman; Marcelo J Kuroda; Jörn E Schmitz; Sampa Santra; Fred W Peyerl; Georgia R Krivulka; Kristin Beaudry; Michelle A Lifton; Darci A Gorgone; David C Montefiori; Mark G Lewis; Steven M Wolinsky; Norman L Letvin
Journal:  Nature       Date:  2002-01-17       Impact factor: 49.962

10.  CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication.

Authors:  C M Walker; D J Moody; D P Stites; J A Levy
Journal:  Science       Date:  1986-12-19       Impact factor: 47.728
View more
  26 in total

Review 1.  Cancer vaccines: progress reveals new complexities.

Authors:  Zhiya Yu; Nicholas P Restifo
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

Review 2.  Exploiting dendritic cells to improve vaccine efficacy.

Authors:  Ralph M Steinman; Melissa Pope
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

3.  New directions in vaccine research.

Authors:  Peter Palese; Adolfo García-Sastre
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

Review 4.  Influenza vaccines: present and future.

Authors:  Peter Palese; Adolfo García-Sastre
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

5.  Generation of CD8+ T-cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 Env.

Authors:  Mark J Cayabyab; Avi-Hai Hovav; Tsungda Hsu; Georgia R Krivulka; Michelle A Lifton; Darci A Gorgone; Glenn J Fennelly; Barton F Haynes; William R Jacobs; Norman L Letvin
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

6.  Identification of immunogenic HLA-B7 "Achilles' heel" epitopes within highly conserved regions of HIV.

Authors:  Anne S De Groot; Daniel S Rivera; Julie A McMurry; Soren Buus; William Martin
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 3.641

7.  Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4.

Authors:  Theresa L-Y Chang; Chia-Hwa Chang; David A Simpson; Qiang Xu; Patrick K Martin; Laurel A Lagenaur; Gary K Schoolnik; David D Ho; Sharon L Hillier; Mark Holodniy; John A Lewicki; Peter P Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-12       Impact factor: 11.205

8.  Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles.

Authors:  Hongtao Zhang; Yujun Huang; Raja Fayad; Gregory T Spear; Liang Qiao
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

9.  Molecular characterization of heterologous HIV-1gp120 gene expression disruption in mycobacterium bovis BCG host strain: a critical issue for engineering mycobacterial based-vaccine vectors.

Authors:  Joan Joseph; Raquel Fernández-Lloris; Elías Pezzat; Narcís Saubi; Pere-Joan Cardona; Beatriz Mothe; Josep Maria Gatell
Journal:  J Biomed Biotechnol       Date:  2010-06-27

Review 10.  Progress on new vaccine strategies against chronic viral infections.

Authors:  Jay A Berzofsky; Jeffrey D Ahlers; John Janik; John Morris; SangKon Oh; Masaki Terabe; Igor M Belyakov
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.